12,372 trials
Acute Migraine With or Without Aura in Adolescents
Primary: Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose — 322 participants
Diabetes Mellitus, Type 2 · End-Stage Kidney Disease
Primary: Change From Baseline in Hemoglobin A1c After Sitagliptin Treatment — 7.89; 7.15; -0.74 Percent hemoglobin A1c — p=<0.001
Paget's Disease of Bone
Primary: Number of Patients Who Had Therapeutic Response at 6 Months — 84; 67 participants
Cervical Cancer · Precancerous Condition
Primary: Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical…
Tuberous Sclerosis · Subependymal Giant Cell Astrocytoma
Primary: Percentage of Participants With Best Overall Subependymal Giant Cell Astrocytomas (SEGA) Response — 34.6; 0.0; 57.7 Percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48 — 87.9; 78.3; 81.7 unit on a scale — p=< 0.0001
Aspergillosis
Primary: All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis — 26; 39 participants — p=0.0434
HIV Infections
Primary: Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline — 4.854; 4.861; 4.840 log10 copies/milliliter(log10 copies/mL)
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12 — 24.90; 24.86; 23.79; 23.78 Millimeters of Mercury (mmHg)
Periodontitis
Primary: HbA1c Levels in Blood — 11.42; 10.81 percentage of HbA1c levels in blood — p=0.05
Hyperhidrosis
Primary: Percentage of Responders Assessed by Gravimetric Measurement at Week 4 in the First Treatment Phase — 96.2; 45.9 percentage of participants — p=<0.001
Influenza
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 2; 3; 1; 0 Participants
Cataract
Primary: Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up — 227; 255 participants — p=0.03
HIV Infections
Primary: Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml — -3.16; -3.31; -3.26; -3.20 log10 HIV-1 RNA — p=0.26
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score — -9.1; -10.2 Units on a scale